Esperion Therapeutics ESPR Capitalized research and development
Capitalized research and development at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopment.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's capitalized research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's capitalized research and development?
- Esperion Therapeutics (ESPR) reported capitalized research and development of $26.13M in Q4 2025.
- How has Esperion Therapeutics's capitalized research and development changed year-over-year?
- Esperion Therapeutics's capitalized research and development decreased by 31.0% year-over-year, from $37.85M to $26.13M.
- What does capitalized research and development mean?
- This reflects the deferred tax asset created by the capitalization of research and development expenditures for tax purposes. It accounts for the timing difference between when R&D costs are expensed for financial reporting and when they are amortized for tax reporting. It serves as an indicator of the company's investment in innovation and its future tax shield potential.